Skip to main content

Table 3 Adverse events in stage 2

From: Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial

Adverse event

Number of adverse events in study

Infusion dose (mg/kg)

1

3

6

hypoglycemia

5

7

24

infusion reactions

0

10

0

URI

13

16

4

diarrhea

0

11

0

pyrexia

1

6

0

cough

3

4

0

sinusitis

4

2

0

otitis media

4

2

0

skin rash

1

4

0

back pain

3

0

2

impetigo

3

0

2

  1. Adverse events listed were observed 5 or more times during course of 52-week study.